Young women of African descent risk a more aggressive form of breast cancer disease, known as triple-negative breast cancer.

Scientists have made significant strides in predicting the severity of triple-negative breast cancer, a particularly aggressive type of the disease....

WEDNESDAY, Sept. 18, 2024 -- Black women have a higher risk of dying from any type of breast cancer than white women, a new review finds. Overall, the...

NVS' breast cancer drug Kisqali reduces the risk of disease recurrence by 28.5% in a broad population of patients suffering from early breast cancer.

Researchers at Baylor College of Medicine and collaborating institutions have discovered new insights into tumor-induced B cell changes in blood and...

The FDA approves NVS' Kisqali to reduce the risk of disease recurrence in patients with HR+/HER2- early breast cancer.

Breakthrough in triple-negative breast cancer diagnosis: New test improves early detection, offering better outcomes and personalized treatment...

Researchers examine the association between patient-derived xenograft with recurrence and survival rates in triple negative breast cancer patients.

According to two international studies presented at the ESMO Congress 2024, women who breastfeed after receiving treatment for breast cancer,...

Heart disease risk assessment tools specific to women remain lacking, despite the fact cardiovascular disease is the leading cause of mortality in...